Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer? (Q36381261)

13 August 2017

1 reference

title

Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer? (English)

1 reference

13 August 2017

1 reference

Antonio Saha

1

1 reference

13 August 2017

Robin Rudd

series ordinal

2

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

165-173

1 reference

Global cancer statistics, 2002

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Epidemiology of Lung Cancer*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

A major lung cancer susceptibility locus maps to chromosome 6q23-25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Surgical treatment of non-small cell lung cancer in patients older than seventy years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Treatment of advanced non-small-cell lung cancer with two-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.165

21 January 2018

Identifiers

DOI

10.1586/14737140.6.2.165

1 reference

release_ky7immxei5fofeuvp7e2csehyi

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ky7immxei5fofeuvp7e2csehyi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference